EN DE
Watch Observe Medical Asa for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Observe Medical Asa (OBSRV) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Observe Medical Asa stock NOK 0.75, price NOK 0.84, that is 10.6% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · ISIN NO0010865009

OM Observe Medical Asa logo Thin data Nov 10, 2026

Observe Medical Asa

OBSRV · OL
Expensive, weak quality

Our calculation puts a fair price 11% below what the stock costs today.

Revenue last quarter +27% vs. a year ago.
Expensive Growth (revenue 5y +44.7 %/yr in NOK)
Moderate debt
Fair value kr 0.7510 · Overvalued
Quality 28/100
Loss-making · -109.7% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Observe Medical Asa for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 251.71 kr 0.5550 Fair Value kr 0.7510 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.5550 – kr 251.71 · fair‑value band kr 0.5633 – kr 0.9388 · the kr 0.8400 price screens above the kr 0.7510 fair value. As of Nov 10, 2026.

Follow Observe Medical in your weekly email

Every Wednesday you see whether Observe Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Observe Medical ASA develops and commercialize medical technology products for patients, healthcare professionals, and hospitals in Europe, Asia, and the Americas.

Show moreShow less

The company offers UnoMeter portfolio comprising Unometer, Safeti Plus, Unometer 500, and UnoMeter AbdoPressure products used for manual urine output measurement and for measuring intra-abdominal pressure.

It also provides Sippi, a digital and automated urine measurement system for urine monitoring and biofilm control. Observe Medical ASA was founded in 2009 and is headquartered in Oslo, Norway.

Stock analysis

Observe Medical Asa (OBSRV) currently trades at kr 0.8400, while our estimate is kr 0.7510, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.5633 (bear) to kr 0.9388 (bull), the price of kr 0.8400 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Observe Medical Asa reported revenue of 18.8M NOK in FY2025 versus 24.0M NOK in FY2021, a compound −5.9%/yr. Reported net income was −48.6M NOK in FY2025.

Key figures

Market cap 114M NOK (≈ $12.0M) Micro · P/S ratio 5.44 · EPS (TTM) kr −0.2300 · Net margin −110% · Return on equity −145% · Return on assets (EBIT) −50.8% (5-year average) · Operating margin −74.4% · Revenue (TTM) 21.9M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 47% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −11%, OBSRV screens richer than that median.

Fair Value

Bear kr 0.5633 Fair Value kr 0.7510 Bull kr 0.9388
Price kr 0.8400 · Downside -10.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 81
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 31
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 65
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−948.5% (2020) → −420.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OBSRV screens overvalued: fair value 11% below the price. Compare with Abbott Laboratories, →

Compare Observe Medical Asa with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −10.6% · Above median
Profitability
Return on assets −48.1% · Bottom 25%
Net margin (12 months) −109.7% · Bottom 25%
Operating margin (12 months) −74.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 27.4% · Top 25%
Balance sheet
Debt / equity 0.67× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.82× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 5.22× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)67 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs OBSRV
DexCom, Inc DXCM $79.92 $89.18 +12% vs OBSRV
Stryker Corporation SYK $324.29 $358.30 +10% vs OBSRV
STERIS plc STE $257.12 $279.53 +9% vs OBSRV
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs OBSRV
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs OBSRV
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs OBSRV
Abbott Laboratories, ABT $110.46 $75.28 −32% vs OBSRV
Medtronic plc MDT $101.59 $65.61 −35% vs OBSRV
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs OBSRV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Observe Medical Asa: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Observe Medical Asa Fair Value". https://www.fairvalue-calculator.com/stock/OBSRV

Frequently asked questions

Is Observe Medical Asa (OBSRV) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.7510 versus a price of kr 0.8400, about 11% lower (overvalued).
What is the fair value of OBSRV?
Our estimate for Observe Medical Asa is kr 0.7510 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.8400.
What is the quality score of OBSRV?
Observe Medical Asa has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Observe Medical Asa (OBSRV)?
Our calculated price target is the estimate of kr 0.7510 (as of Nov 10, 2026). Cautious scenario kr 0.5633, optimistic scenario kr 0.9388. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Observe Medical Asa stock forecast for 2026?
Our estimate puts fair value at kr 0.7510, about 11% lower versus a price of kr 0.8400 (overvalued). Cautious scenario kr 0.5633, optimistic scenario kr 0.9388. The calculation is refreshed regularly with new filings.
What is the revenue of Observe Medical Asa (OBSRV)?
Observe Medical Asa reported trailing-twelve-month revenue of about 21.9M NOK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Observe Medical Asa (OBSRV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Observe Medical Asa it is kr 0.7510 per share (as of Nov 10, 2026), against a price of kr 0.8400.
Is Observe Medical Asa stock overvalued or undervalued in 2026?
As of Nov 10, 2026, OBSRV trades above its calculated fair value: price kr 0.8400, fair value kr 0.7510, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBSRV?
No. The price is what the market pays today (kr 0.8400); the fair value is what the company's own numbers justify (kr 0.7510). For Observe Medical Asa the two are kr 0.0890 per share apart. That gap is exactly why we show both numbers side by side.
How much is Observe Medical Asa worth?
The market values Observe Medical Asa at about 114M NOK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.8400; our models calculate a fair value of kr 0.7510 per share.
What do the bullish and bearish scenarios say about OBSRV?
Our models span a range for Observe Medical Asa: cautious scenario kr 0.5633, base kr 0.7510, optimistic kr 0.9388 per share (as of Nov 10, 2026, price kr 0.8400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Observe Medical Asa (OBSRV)?
Balance-sheet figures for Observe Medical Asa (as of Nov 10, 2026): return on equity −145.5%, debt of 0.67 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is OBSRV from its 52-week high?
Observe Medical Asa trades at kr 0.8400, about 33% below its 52-week high of kr 1.25 and 47% above the low of kr 0.5700 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.7510 is for.
Which stocks are comparable to Observe Medical Asa?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Observe Medical Asa stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.8400, calculated fair value kr 0.7510 (−11%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Observe Medical Asa itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Observe Medical Asa (OBSRV)?
The closing price on Nov 10, 2026 was kr 0.8400. Our estimate is kr 0.7510, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Observe Medical Asa right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Observe Medical Asa

How large is the market capitalisation of Observe Medical Asa (OBSRV)?
The market capitalisation of Observe Medical Asa is 114M NOK (≈ $12.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Observe Medical Asa (OBSRV)?
The price-to-sales ratio of Observe Medical Asa is 5.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Observe Medical Asa (OBSRV)?
Earnings per share at Observe Medical Asa are kr −0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Observe Medical Asa (OBSRV)?
The net margin of Observe Medical Asa is −110% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Observe Medical Asa (OBSRV)?
The return on equity (ROE) of Observe Medical Asa is −145% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Observe Medical Asa (OBSRV)?
On an EBIT basis the return on assets of Observe Medical Asa is −50.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Observe Medical Asa (OBSRV)?
The operating margin of Observe Medical Asa is −74.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Observe Medical Asa (OBSRV)?
Revenue at Observe Medical Asa is growing +27.4% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Observe Medical Asa (OBSRV) generate?
The free cash flow of Observe Medical Asa is −26.0M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Observe Medical Asa (OBSRV) carry?
The net debt of Observe Medical Asa is 19.2M NOK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Observe Medical Asa in the live analysis

One click puts Observe Medical Asa on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.